Lyka Generics Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 17-07-2024
- Paid Up Capital ₹ 0.50 M
as on 17-07-2024
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.25 Cr
as on 17-07-2024
- Satisfied Charges ₹ 3.68 M
as on 17-07-2024
- Revenue -59.49%
(FY 2023)
- Profit -84.81%
(FY 2023)
- Ebitda -103.94%
(FY 2023)
- Net Worth 14.83%
(FY 2023)
- Total Assets 41.93%
(FY 2023)
About Lyka Generics
The Corporate was formerly known as Lyka Animal Healthcare Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.25 Cr. The company has closed loans amounting to ₹3.68 M, as per Ministry of Corporate Affairs (MCA) records.
Narendra Rathod, Alisha Gandhi, and Kunal Gandhi serve as directors at the Company.
- CIN/LLPIN
U85100MH2013PLC241035
- Company No.
241035
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2013
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Lyka Generics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narendra Rathod  | Director | 10-Oct-2022 | Current |
| Alisha Gandhi | Director | 01-Aug-2019 | Current |
| Kunal Gandhi | Director | 16-Mar-2013 | Current |
Financial Performance and Corporate Structure Insights of Lyka Generics.
Lyka Generics Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 59.49% decrease. The company also saw a substantial fall in profitability, with a 84.81% decrease in profit. The company's net worth Soared by an impressive increase of 14.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lyka Generics?
In 2023, Lyka Generics had a promoter holding of 99.99% and a public holding of 0.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Enai Trading And Investment Private LimitedActive 31 years 27 daysNarendra Rathod and Kunal Gandhi are mutual person
- Hiralaxmi Business Finance Private LimitedActive 40 years 10 months
Narendra Rathod and Kunal Gandhi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 03 Mar 2023 | ₹2.25 Cr | Open |
Others Creation Date: 28 Jan 2020 | ₹3.68 M | Satisfied |
How Many Employees Work at Lyka Generics?
Unlock and access historical data on people associated with Lyka Generics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lyka Generics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lyka Generics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
